Insider Purchases: Inside the Buy

Tag: Intellia Therapeutics

DNA stock chart tug-of-war between shorts and insider buyers for Intellia (NTLA).

Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?

NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.

Read entire article

Tags: Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, Biotech Investments, biotech jokes, Biotech Picks, buy-or-sell-ntla, clinical-trials, CRISPR, CRISPR Gene Editing, death-in-trial, fda, fda-hold, featured-epiphany, featured-insiders, funstock-index, gene-editing, healthcare-stocks, high-risk-high-reward, hub-epiphany, hub-insiders, insider-buys, Intellia Therapeutics, nasdaq, Ntla, risks-buying-ntla, short-interest, speculative-stocks, spotlight-health, why-buy-ntla